Lactobacillus gasseri 관련 Helicobacter pylori Infection
BThree RCTs show L. gasseri LG21 suppresses H. pylori load and improves eradication rates when combined with standard triple therapy. Also improves GERD symptoms.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dlactobacillus\u002Dgasseri\u0026condition\u003Dh\u002Dpylori';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
결론
Three RCTs show L. gasseri LG21 suppresses H. pylori load and improves eradication rates when combined with standard triple therapy. Also improves GERD symptoms.
Key Study Findings
In Vitro
Lactobacillus gasseri suppresses the Helicobacter pylori-induced expression of the proliferation-associated factors HBEGF and TGF-α in …
Dose: None
vs: H. pylori infection without lactobacilli
Outcome: ADAM17, HBEGF, TGF-alpha expression
효과: None
None
대상 집단: AGS gastric epithelial cells and mouse model
In Vitro
Lactobacillus gasseri Suppresses the Helicobacter pylori-Induced Hummingbird Phenotype by Inhibiting CagA Phosphorylation and SHP-2 Interaction.
Dose: None
vs: CagA-expressing AGS cells without L. gasseri
Outcome: Suppression of CagA phosphorylation (hummingbird)
효과: None
None
대상 집단: Human gastric AGS cell line with H. pylori CagA
In Vitro
The modulatory effect of Lactobacillus gasseri ATCC 33323 on autophagy induced by extracellular vesicles of …
Dose: 50 μg/ml
vs: None
Outcome: Inflammatory markers
효과: None
None
대상 집단: None
Other
Effect of Lactobacillus gasseri BIO6369 and Lacticaseibacillus rhamnosus BIO5326 on Gastric Carcinogenesis Induced by Helicobacter …
Dose: None
vs: None
Outcome: Inflammatory markers
효과: None
None
대상 집단: Cancer patients
Other
Two novel lactic acid bacteria, Limosilactobacillus fermentum MN-LF23 and Lactobacillus gasseri MN-LG80, inhibited Helicobacter pylori …
Dose: None
vs: None
Outcome: H. pylori abundance reduction
효과: None
None
대상 집단: H. pylori-infected C57BL/6 mice
Case-Control
n=178
Oral and gastric microbiome in relation to gastric intestinal metaplasia.
Dose: None
vs: None
Outcome: Oral/gastric microbiome associations with IM
효과: None
None
대상 집단: Gastric intestinal metaplasia cases and matched controls
Key Statistics
3
연구
350
참여자
↑
Positive
B
등급
Referenced Papers
International journal of …
2025
4 인용
International journal of …
2025
Microbial pathogenesis
2024
8 인용
Helicobacter
2024
5 인용
International journal of …
2022
59 인용
BMC microbiology
2022
28 인용
Food & function
2022
19 인용
Probiotics and antimicrobial …
2021
30 인용
Comparative immunology, microbiology …
2019
72 인용
Frontiers in immunology
2019
61 인용
Frontiers in microbiology
2019
31 인용
BMJ open gastroenterology
2019
14 인용
Digestion
2017
67 인용
Gastroenterology research and …
2016
38 인용
Helicobacter
2015
26 인용
PloS one
2014
171 인용
Frontiers in microbiology
2014
78 인용
Genomic and phenotypic evidence for probiotic influences of Lactobacillus gasseri on human health.
Review
FEMS microbiology reviews
2013
196 인용
Journal of gastroenterology …
2012
76 인용
Journal of food …
2012
56 인용
Journal of clinical …
2012
37 인용
Journal of dairy …
2010
43 인용
Journal of medicinal …
2010
19 인용
Probiotics and antimicrobial …
2010
9 인용
Helicobacter
2009
48 인용
Cellular microbiology
2006
50 인용
Journal of gastroenterology …
2006
41 인용
Letters in applied …
2006
26 인용
Journal of pharmacological …
2004
58 인용
Journal of gastroenterology …
2003
77 인용
Effects of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in children.
Other
The Journal of …
2002
31 인용
The Journal of …
2001
309 인용
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 1-10 billion CFU/day
- gerdsupport:
- 1-5 billion CFU/day
- hpylorisupport:
- 100 million CFU/day (LG21 strain, yogurt form) for 8-12 weeks
상한량: Well-tolerated up to 10 billion CFU/day in clinical trials
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| 50 μg/ml | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Neutral | 178 |
| None | -- | Positive | -- |
| 1 g | -- | Positive | -- |
권장 복용 시간: Before meals or with meals; yogurt form taken with food
Safety & Side Effects
보고된 부작용
- ⚠ Mild gas during initial use
- ⚠ Occasional loose stools
- ⚠ Rare abdominal discomfort
- ⚠ Very rare: bacteremia in immunocompromised individuals
알려진 상호작용
- ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
- ● Proton pump inhibitors (altered gastric pH may affect colonization)
- ● Immunosuppressants (theoretical risk in immunocompromised patients)
일일 최대 섭취 허용량: Well-tolerated up to 10 billion CFU/day in clinical trials
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does Lactobacillus gasseri help with Helicobacter pylori Infection?
Based on 3 studies with 350 participants, there is moderate evidence from clinical studies that Lactobacillus gasseri may support Helicobacter pylori Infection management. Our evidence grade is B (Good Evidence).
How much Lactobacillus gasseri should I take for Helicobacter pylori Infection?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus gasseri?
Reported side effects may include Mild gas during initial use, Occasional loose stools, Rare abdominal discomfort, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus gasseri and Helicobacter pylori Infection?
We rate the evidence as Grade B (Good Evidence). This rating is based on 3 peer-reviewed studies with 350 total participants. The overall direction of effect is positive.
Related Evidence
관련 다른 성분: Helicobacter pylori Infection
Lactobacillus gasseri 다른 건강 상태에 대한 근거
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.